User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma.

Primary tabs

Nols, Nathalie [UCL] Mounier, Nicolas Bouazza, Salima [UCL] Lhommel, Renaud [UCL] Costantini, Sabrina [UCL] Vander Borght, Thierry [UCL] Vekemans, Marie-Christiane [UCL] Sonet, Anne [UCL] Bosly, André [UCL] Michaux, Lucienne [UCL] André, Marc [UCL] Van Den Neste, Eric [UCL]

The prognostic value of interim (18)fluorodeoxyglucose positron emission tomography (i-PET) was investigated in 73 patients (median age 60 years) with diffuse large B-cell lymphoma (DLBCL). i-PET was analyzed using the Deauville score (DS) and change in maximum standardized uptake value (ΔSUVmax). Patients with a DS of 1-3 demonstrated a significantly (p < 0.0001) better outcome (median follow-up 2.4 years) than patients with a score of 4 or 5 in terms of event-free survival (EFS) (79% vs. 36%), progression-free survival (PFS) (84% vs. 47%) and overall survival (OS) (91% vs. 51%). EFS (73% vs. 42%), PFS (78% vs. 50%) and OS (88% vs. 56%) were also significantly (p = 0.023) different between patients with ΔSUVmax > 66% or ≤ 66%. Patients (n = 33) combining a favorable age-adjusted International Prognostic Index (IPI) (0 or 1) and a negative i-PET either by DS or ΔSUVmax criteria showed a particularly good outcome (EFS: 85%, PFS: 88%, OS: 94%). Overall, i-PET was highly and independently predictive of any outcome, and its negative predictive value was improved by combination with IPI.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2014
Language Anglais
Journal information "Leukemia and Lymphoma" - Vol. 55, no. 4, p. 773-780 (2014)
Peer reviewed yes
Publisher Informa Healthcare ((United Kingdom) London)
issn 1042-8194
e-issn 1029-2403
Publication status Publié
Affiliations UCL - (SLuc) Service de médecine nucléaire
UCL - (SLuc) Service d'hématologie
UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - (MGD) Service de médecine nucléaire
UCL - (MGD) Service d'hématologie
UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie
UCL - SSS/DDUV - Institut de Duve
UCL - (SLuc) Service d'hématologie
UCL - (SLuc) Service de médecine nucléaire
UCL - SSS/IONS - Institute of NeuroScience
UCL - SSS/IONS/NEUR - Clinical Neuroscience
Links
  1. Coiffier B., Thieblemont C., Van Den Neste E., Lepeu G., Plantier I., Castaigne S., Lefort S., Marit G., Macro M., Sebban C., Belhadj K., Bordessoule D., Ferme C., Tilly H., Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte, 10.1182/blood-2010-03-276246
  2. Moskowitz CH, J Natl Compr Canc Netw, 8, 347 (2010)
  3. Itti E., Juweid M. E., Haioun C., Yeddes I., Hamza-Maaloul F., El Bez I., Evangelista E., Lin C., Dupuis J., Meignan M., Improvement of Early 18F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background, 10.2967/jnumed.110.080556
  4. Meignan Michel, Gallamini Andrea, Meignan Michel, Gallamini Andrea, Haioun Corinne, Report on the First International Workshop on interim-PET scan in lymphoma, 10.1080/10428190903040048
  5. Meignan Michel, Gallamini Andrea, Haioun Corinne, Polliack Aaron, Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010, 10.3109/10428194.2010.529208
  6. Lin C., Itti E., Haioun C., Petegnief Y., Luciani A., Dupuis J., Paone G., Talbot J.-N., Rahmouni A., Meignan M., Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis, 10.2967/jnumed.107.042093
  7. Cheson Bruce D., Pfistner Beate, Juweid Malik E., Gascoyne Randy D., Specht Lena, Horning Sandra J., Coiffier Bertrand, Fisher Richard I., Hagenbeek Anton, Zucca Emanuele, Rosen Steven T., Stroobants Sigrid, Lister T. Andrew, Hoppe Richard T., Dreyling Martin, Tobinai Kensei, Vose Julie M., Connors Joseph M., Federico Massimo, Diehl Volker, Revised Response Criteria for Malignant Lymphoma, 10.1200/jco.2006.09.2403
  8. Mounier N., Gisselbrecht C., Brière J., Haioun C., Feugier P., Offner F., Recher C., Stamatoullas A., Morschhauser F., Macro M., Thieblemont C., Sonet A., Fabiani B., Reyes F., Prognostic Factors in Patients With Aggressive Non-Hodgkin's Lymphoma Treated by Front-Line Autotransplantation After Complete Remission: A Cohort Study by the Groupe d'Etude des Lymphomes de l'Adulte, 10.1200/jco.2004.12.032
  9. Horning S. J., Juweid M. E., Schoder H., Wiseman G., McMillan A., Swinnen L. J., Advani R., Gascoyne R., Quon A., Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study, 10.1182/blood-2009-08-234351
  10. Casasnovas R.-O., Meignan M., Berriolo-Riedinger A., Bardet S., Julian A., Thieblemont C., Vera P., Bologna S., Briere J., Jais J.-P., Haioun C., Coiffier B., Morschhauser F., , SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma, 10.1182/blood-2010-12-327767
  11. Michallet Anne-Sophie, Trotman Judith, Tychyj-Pinel Christelle, Role of early PET in the management of diffuse large B-cell lymphoma : , 10.1097/cco.0b013e32833d5905
  12. Dunleavy Kieron, Mikhaeel George, Sehn Laurie H., Hicks Rodney J., Wilson Wyndham H., The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma, 10.3109/10428194.2010.500051
  13. Hüttmann Andreas, Müller Stefan, Jöckel Karl-Heinz, Dührsen Ulrich, Pitfalls of Interim Positron Emission Tomography Scanning in Diffuse Large B-Cell Lymphoma, 10.1200/jco.2010.29.5428
  14. Juweid Malik E., Smith Brian, Itti Emmanuel, Meignan Michel, Can the Interim Fluorodeoxyglucose–Positron Emission Tomography Standardized Uptake Value Be Used to Determine the Need for Residual Mass Biopsy After Dose-Dense Immunochemotherapy for Advanced Diffuse Large B-Cell Lymphoma?, 10.1200/jco.2010.30.4394
  15. Jerusalem G, Haematologica, 85, 613 (2000)
  16. Mikhaeel N. G., Timothy A. R., O'Doherty M. J., Hain S., Maisey M. N., 18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT, 10.3109/10428190009113384
  17. Spaepen K., Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma, 10.1093/annonc/mdf256
  18. Kostakoglu L, J Nucl Med, 43, 1018 (2002)
  19. Itti E., Lin C., Dupuis J., Paone G., Capacchione D., Rahmouni A., Haioun C., Meignan M., Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy, 10.2967/jnumed.108.057703
  20. Haioun C., [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome, 10.1182/blood-2005-01-0272
  21. Mikhaeel N. G., Hutchings M., Fields P. A., O'Doherty M. J., Timothy A. R., FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma, 10.1093/annonc/mdi272
  22. Yang Deok-Hwan, Min Jung-Joon, Song Ho-Chun, Jeong Yong Yeon, Chung Woong-Ki, Bae Soo-Young, Ahn Jae-Sook, Kim Yeo-Kyeoung, Bom Hee-Seung, Chung Ik-Joo, Kim Hyeoung-Joon, Lee Je-Jung, Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma, 10.1016/j.ejca.2010.12.027
  23. Safar Violaine, Dupuis Jehan, Itti Emmanuel, Jardin Fabrice, Fruchart Christophe, Bardet Stéphane, Véra Pierre, Copie-Bergman Christiane, Rahmouni Alain, Tilly Hervé, Meignan Michel, Haioun Corinne, Interim [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab, 10.1200/jco.2011.38.2648
  24. Pregno P., Chiappella A., Bello M., Botto B., Ferrero S., Franceschetti S., Giunta F., Ladetto M., Limerutti G., Menga M., Nicolosi M., Priolo G., Puccini B., Rigacci L., Salvi F., Vaggelli L., Passera R., Bisi G., Vitolo U., Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP, 10.1182/blood-2011-06-359943
  25. Moskowitz Craig H., Schöder Heiko, Teruya-Feldstein Julie, Sima Camelia, Iasonos Alexia, Portlock Carol S., Straus David, Noy Ariela, Palomba Maria L., O'Connor Owen A., Horwitz Steven, Weaver Sarah A., Meikle Jessica L., Filippa Daniel A., Caravelli James F., Hamlin Paul A., Zelenetz Andrew D., Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma, 10.1200/jco.2009.26.5942
  26. Moskowitz CH, Hematology Am Soc Hematol Educ Program, 397 (2012)
  27. Terasawa Teruhiko, Nagai Hirokazu, Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes, 10.3109/10428190903308080
  28. Meignan Michel, Interim PET in lymphoma: a step towards standardization, 10.1007/s00259-010-1546-6
  29. Cashen A. F., Dehdashti F., Luo J., Homb A., Siegel B. A., Bartlett N. L., 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation, 10.2967/jnumed.110.082586
  30. Yoo Changhoon, Lee Dae Ho, Kim Jeong Eun, Jo Jungmin, Yoon Dok Hyun, Sohn Byeong Seok, Kim Sang-We, Lee Jung-Shin, Suh Cheolwon, Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP, 10.1007/s00277-010-1135-6
  31. Han H. S., Escalon M. P., Hsiao B., Serafini A., Lossos I. S., High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens, 10.1093/annonc/mdn629
  32. Kasamon Yvette L., Wahl Richard L., Ziessman Harvey A., Blackford Amanda L., Goodman Steven N., Fidyk Caroline A., Rogers Kathryn M., Bolaños-Meade Javier, Borowitz Michael J., Ambinder Richard F., Jones Richard J., Swinnen Lode J., Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning, 10.1016/j.bbmt.2008.11.026
  33. Casasnovas R-O, Blood, 120 (2012)
  34. Fields PA, Haematologica, 90, 1711 (2005)
  35. De Paepe Katja, Bevernage Charlotte, De Keyzer Frederik, Wolter Pascal, Gheysens Olivier, Janssens Ann, Oyen Raymond, Verhoef Gregor, Vandecaveye Vincent, Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study, 10.1102/1470-7330.2013.0006
Bibliographic reference Nols, Nathalie ; Mounier, Nicolas ; Bouazza, Salima ; Lhommel, Renaud ; Costantini, Sabrina ; et. al. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma.. In: Leukemia and Lymphoma, Vol. 55, no. 4, p. 773-780 (2014)
Permanent URL http://hdl.handle.net/2078.1/133836